Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 141 No. 2930 (2011)

Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I) – an observational survey in lower respiratory tract infections

  • K Rüegger
  • F Dusemund
  • R Bossart
  • K Regez
  • U Schild
  • A Conca
  • T Sigrist
  • B Reutlinger
DOI
https://doi.org/10.4414/smw.2011.13237
Cite this as:
Swiss Med Wkly. 2011;141:w13237
Published
18.07.2011

Summary

BACKGROUND:Current medical scores have limited efficiency and safety profiles to enable assignment to the most appropriate treatment site in patients with lower respiratory tract infections (LRTIs). We describe our current triage practice and assess the potential of a combination of CURB65 with proadrenomedullin (ProADM) levels for triage decisions.

METHODS:Consecutive patients with LRTIs presenting to our emergency department were prospectively followed and retrospectively classified according to CURB65 and ProADM levels (CURB65-A). Low medical risk patients were further subgrouped according to biopsychosocial and functional risks. We compared the proportion of patients virtually allocated to triage sites with actual triage decisions and assessed the added impact of ProADM in a subgroup.

RESULTS:Overall, 93% of 146 patients were hospitalised. Among the 138 patients with available CURB65-A, 17.4% had a low medical risk indicating possible treatment in an outpatient or non-acute medical setting; 34.1% had an intermediate medical risk (short-hospitalisation); and 48.6% had a high medical risk (hospitalisation). Fewer patients were in a low CURB65-A class (I) than a low CURB65 class (0,1) (17.4% vs. 46.3%, p <0.001). Mean length of hospitalisation was 9.8 days including 3.6 days after reaching medical stability. In 60.3% of patients, hospitalisation was prolonged after medical stability mainly for medical reasons.

CONCLUSIONS:Current rates of hospitalisation are high in patients with LRTI and length of stay frequently extended beyond time of medical stabilization. The lower proportion of patients reclassified as low risk by adding ProADM to the CURB65 score might improve confidence in the triage algorithm.

 

Trial registration ISRCTN76703125

References

  1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20(4):820–37.
  2. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection. 2004;32(4):234–8.
  3. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15(4):757–63.
  4. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in “low-risk” community acquired pneumonia. BMC Infect Dis. 2003;3:11.
  5. Marrie TJ. Risks and outcomes in community acquired pneumonia. Can Respir J. 1999;6(Suppl A):6A–9A.
  6. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50.
  7. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–82.
  8. Aujesky D, McCausland JB, Whittle J, Obrosky DS, Yealy DM, Fine MJ. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis. 2009;49(10):e100–108.
  9. Carratala J, Fernandez-Sabe N, Ortega L, Castellsague X, Roson B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142(3):165–72.
  10. Baehni C, Meier S, Spreiter P, Schild U, Regez K, Bossart R, et al. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulm Med. 10:12.
  11. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.
  12. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10(3):R96.
  13. Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, Bingisser R, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176(9):913–20.
  14. Gruber M, Christ-Crain M, Stolz D, Keller U, Muller C, Bingisser R, et al. Prognostic impact of plasma lipids in patients with lower respiratory tract infections – an observational study. Swiss Med Wkly. 2009;139(11–12):166–72.
  15. Schuetz P, Stolz D, Mueller B, Morgenthaler NG, Struck J, Mueller C, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis. 2008;8:22.
  16. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009;136(3):823–31.
  17. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 14(3):R106.
  18. Becker KL, Nylen ES, White JC, Muller B, Snider RH, Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4):1512–25.
  19. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther. 2004;103(3):179–201.
  20. Albrich WC, Dusemund F, Rüegger K, Christ-Crain M, Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm. BMC Infect Dis. 2011;11:112.
  21. große Schlarmann J. Der CMS© im ePA©. Verschiedene Qualitätsdimensionen eines Instruments. Eine empirische Analyse. Gelsenkirchen: Private Universität Witten/Herdecke gGmbH; 2007.
  22. Louis Simonet M, Kossovsky MP, Chopard P, Sigaud P, Perneger TV, Gaspoz JM. A predictive score to identify hospitalized patients’ risk of discharge to a post-acute care facility. BMC Health Serv Res. 2008;8:154.
  23. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000–2007; discussion 2007–2008.
  24. Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Muller B, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006;136(27-28):434–40.
  25. Schuetz P, Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2010.
  26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
  27. Goring H, Baldwin R, Marriott A, Pratt H, Roberts C. Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients. Int J Geriatr Psychiatry. 2004;19(5):465–71.
  28. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51(10):1823–9.
  29. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730–54.
  30. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis. 2000;31(4):1066–78.
  31. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133(12):981–91.
  32. Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156(14):1565–71.
  33. Fried TR, van Doorn C, O’Leary JR, Tinetti ME, Drickamer MA. Older person’s preferences for home vs hospital care in the treatment of acute illness. Arch Intern Med. 2000;160(10):1501–6.
  34. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127(4):1260–70.
  35. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J. 2007;14(4):212–6.
  36. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Summary of Canadian Guidelines for the Initial Management of Community-acquired Pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000;11(5):237–48.
  37. Loeb M, Carusone SC, Goeree R, Walter SD, Brazil K, Krueger P, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA. 2006;295(21):2503–10.
  38. Labarere J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med. 2006;21(7):745–52.
  39. Mandell L. Decisions about treating community-acquired pneumonia. Ann Intern Med. 2005;142(3):215–6.
  40. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297(16):1772–4.
  41. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158(12):1350–6.
  42. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166(5):717–23.
  43. Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnoea. Arch Intern Med. 2006;166(10):1081–7.
  44. Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A, et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Invest. 2010;41(3):315–22.
  45. Reinhold T, Berghofer A, Willich SN. Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example. Herz. 2010;35(1):1–10.